Cardiovascular disease biomarkers across autoimmune diseases

Copyright © 2015 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 161(2015), 1 vom: 03. Nov., Seite 59-63
1. Verfasser: Ahearn, Joseph (VerfasserIn)
Weitere Verfasser: Shields, Kelly J, Liu, Chau-Ching, Manzi, Susan
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2015
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Review Atherosclerosis Autoimmune Biomarkers Cardiovascular Lupus Rheumatoid Lipoproteins, HDL Calcium SY7Q814VUP
LEADER 01000naa a22002652 4500
001 NLM250825341
003 DE-627
005 20231224160649.0
007 cr uuu---uuuuu
008 231224s2015 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2015.05.024  |2 doi 
028 5 2 |a pubmed24n0836.xml 
035 |a (DE-627)NLM250825341 
035 |a (NLM)26168705 
035 |a (PII)S1521-6616(15)00220-X 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Ahearn, Joseph  |e verfasserin  |4 aut 
245 1 0 |a Cardiovascular disease biomarkers across autoimmune diseases 
264 1 |c 2015 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 01.04.2016 
500 |a Date Revised 30.10.2015 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2015 Elsevier Inc. All rights reserved. 
520 |a Cardiovascular disease is increasingly recognized as a major cause of premature mortality among those with autoimmune disorders. There is an urgent need to identify those patients with autoimmune disease who are at risk for CVD so as to optimize therapeutic intervention and ultimately prevention. Accurate identification, monitoring and stratification of such patients will depend upon a panel of biomarkers of cardiovascular disease. This review will discuss some of the most recent biomarkers of cardiovascular diseases in autoimmune disease, including lipid oxidation, imaging biomarkers to characterize coronary calcium, plaque, and intima media thickness, biomarkers of inflammation and activated complement, genetic markers, endothelial biomarkers, and antiphospholipid antibodies. Clinical implementation of these biomarkers will not only enhance patient care but also likely accelerate the pharmaceutical pipeline for targeted intervention to reduce or eliminate cardiovascular disease in the setting of autoimmunity 
650 4 |a Journal Article 
650 4 |a Review 
650 4 |a Atherosclerosis 
650 4 |a Autoimmune 
650 4 |a Biomarkers 
650 4 |a Cardiovascular 
650 4 |a Lupus 
650 4 |a Rheumatoid 
650 7 |a Biomarkers  |2 NLM 
650 7 |a Lipoproteins, HDL  |2 NLM 
650 7 |a Calcium  |2 NLM 
650 7 |a SY7Q814VUP  |2 NLM 
700 1 |a Shields, Kelly J  |e verfasserin  |4 aut 
700 1 |a Liu, Chau-Ching  |e verfasserin  |4 aut 
700 1 |a Manzi, Susan  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 161(2015), 1 vom: 03. Nov., Seite 59-63  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:161  |g year:2015  |g number:1  |g day:03  |g month:11  |g pages:59-63 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2015.05.024  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 161  |j 2015  |e 1  |b 03  |c 11  |h 59-63